🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Fred Hutch is looking for a director of the Fred Hutch Innovation Lab (FHIL). The lab is evaluating, developing, and applying the next generation of genomics and cellular analysis technologies. Take a look at this opportunity to join us in Seattle! careers-fhcrc.icims.com/jobs/21256/dir…

Check out this great opportunity for a physician scientist fellowship at Fred Hutch. apply.interfolio.com/103987

Hey you. This is a wonderful opportunity to come and join us Fred Hutch Cancer Center. Looking for people pursuing exciting areas of immunology or gene therapy as they relate to HCT. Lab-based position (ie, not looking for a physician, although Physician-scientists are of course also welcome!)

The Fred Hutch #Immunotherapy Integrated Research Center (IIRC) seeks qualified candidates for its two-year Immunotherapy Physician Scientist Program. Learn more and apply: apply.interfolio.com/121183

The IIRC is looking for our next #Immunotherapy Physician Scientist Fellow! Please share and follow the link below to learn more and apply: apply.interfolio.com/121183

Using in situ spatial transcriptomics? Try Proseg, @danielcjones’s new cell segmentation method based on probabilistic and Cellular Potts modeling. Great for Vizgen Merscope, 10x Genomics Xenium, and @nanostringtech CosMx data. Preprint & code: (1/n) doi.org/10.1101/2024.0…

We are pleased to share our work evaluating some of the latest single-cell platforms, including updated chemistries, in two separate experiments using peripheral blood mononuclear cells (PBMCs). biorxiv.org/cgi/content/sh…

In pediatric MDS, disease burden at transplant is a key predictor of outcomes. Children with <5% blasts had 87% 2-yr OS, vs. 54% with ≥5%. Single-center data Fred Hutch Cancer Center pubmed.ncbi.nlm.nih.gov/40427141/

Researchers developed a base editing approach to protect immune cells from toxicity in gene therapy. Multiplexed editing of CD33 & gamma globin genes shows promise for more effective gene and immunotherapies. Fred Hutch Cancer Center, @hpkiem pubmed.ncbi.nlm.nih.gov/40425554/

New from @FH_IIRC Evan Newell Fred Hutch Innovation Lab “Cell simulation as cell segmentation,” a novel approach that improves accuracy in identifying tumor-infiltrating immune cells from spatial transcriptomics data. Faster, more precise boundaries across platforms nature.com/articles/s4159…

Mazyar Shadman, MD MPH at @FredHutch was honored with the #Binaytara Distinguished Faculty of the Year Award for improving #CancerCare access and education at #SCHD25. 📖Discover how Dr. Shadman enhances CAR-T access: buff.ly/sZuz5gP 🎯Join our CME/ACPE-accredited events:

Big thanks to Lamar Advertising of Seattle-Tacoma for helping us light up Seattle with Obliteride spirit! Your support helps #CureCancerFaster. 💥🧡

Scenes from the 51st #SeattlePride! #fredhutch

A promising new approach for relapsed Non-Hodgkin Lymphomas? In a small safety study Fred Hutch Cancer Center, high-risk lymphoma patients tolerated B9E9-Fusion Protein pre-targeted radioimmunotherapy (PRIT) combined with stem cell transplant—without major added toxicity. Early signs suggest

Targeting SF3B1 mutations in myelodysplastic neoplasms (MDS) and secondary acute myeloid leukemia (sAML), a new study Fred Hutch Cancer Center finds that neoantigens from SF3B1K700E mutations can induce potent, specific T-cell responses—opening the door to novel immunotherapies for